This report was first published by Endpoints News. To see the original version, click here
BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved rare disease medicines, the California biotech said Friday.
By gaining access to Amicus’ meds for Pompe and Fabry diseases, CEO Alexander Hardy is forging a key part of the future for BioMarin as part of a multiyear turnaround. The drugmaker has conducted layoffs, reorganizations and pipeline culls over the past few years to adjust the ship.
您已閱讀13%（524字），剩余87%（3515字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。